1. Home
  2. HNI vs TARS Comparison

HNI vs TARS Comparison

Compare HNI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HNI Corporation

HNI

HNI Corporation

HOLD

Current Price

$37.21

Market Cap

2.7B

ML Signal

HOLD

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$61.25

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNI
TARS
Founded
1944
2016
Country
United States
United States
Employees
19500
N/A
Industry
Office Equipment/Supplies/Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.7B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
HNI
TARS
Price
$37.21
$61.25
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$70.00
$89.00
AVG Volume (30 Days)
574.4K
413.4K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
3.65%
N/A
EPS Growth
N/A
48.21
EPS
1.11
N/A
Revenue
$2,839,000,000.00
$451,360,000.00
Revenue This Year
$117.19
$56.43
Revenue Next Year
$3.68
$30.19
P/E Ratio
$33.38
N/A
Revenue Growth
12.37
146.71
52 Week Low
$31.41
$38.51
52 Week High
$53.29
$85.25

Technical Indicators

Market Signals
Indicator
HNI
TARS
Relative Strength Index (RSI) 51.98 29.93
Support Level $33.72 $38.85
Resistance Level $47.09 $76.47
Average True Range (ATR) 1.14 3.11
MACD 0.70 -1.04
Stochastic Oscillator 80.32 5.17

Price Performance

Historical Comparison
HNI
TARS

About HNI HNI Corporation

HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Share on Social Networks: